Clinical Trial Update: Avelumab as Single Agent in Metastatic or Locally Advanced Urothelial Cancer in Patients Unfit for Cisplatin. The ARIES Study [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating avelumab as a single agent in metastatic or locally advanced urothelial cancer in patients unfit for cisplatin has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Cancer

Drugs mentioned

• Avelumab (avelumab)

Snippet

Sponsor: Consorzio Oncotech | Conditions: Metastatic or Locally Advanced PD-L1 Positive Urothelial Cancer | Phase 2 | Status: COMPLETED